Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report
© Imbuldeniya et al; licensee BioMed Central Ltd. 2012
Received: 16 September 2011
Accepted: 6 February 2012
Published: 6 February 2012
Atypical insufficiency fractures of the femur in patients on long-term bisphosphonate therapy have been well described in recent literature. The majority of cases are associated with minimal or no trauma and occur in the subtrochanteric or diaphyseal region.
We describe the case of a 76-year-old British Caucasian woman who presented initially to an emergency department and then to her primary care physician with a long-standing history of bilateral knee pain after minor trauma. Plain radiographs showed subtle linear areas of sclerosis bilaterally in her proximal tibiae. Magnetic resonance imaging confirmed the presence of insufficiency fractures in these areas along with her left distal femur. There are very few reports of atypical insufficiency fractures involving the tibia in patients on long-term bisphosphonate therapy and this appears to be the only documented bilateral case involving the metaphyseal regions of the proximal tibia and distal femur.
In addition to existing literature describing atypical fractures in the proximal femur and femoral shaft, there is a need for increased awareness that these fractures can also occur in other weight-bearing areas of the skeleton. All clinicians involved in the care of patients taking long-term bisphosphonates need to be aware of the growing association between new onset lower limb pain and atypical insufficiency fractures.
Atypical subtrochanteric and diaphyseal insufficiency fractures of the femur in association with long-term bisphosphonate use have been well described in recent literature [1–6]. The majority of cases are associated with the most commonly used bisphosphonate alendronate but may also be associated with other antiresorptive agents, corticosteroids and proton pump inhibitors [4, 7].
By causing osteoclast apoptosis, bisphosphonates decrease bone resorption. This results in increased bone mineral density and a decreased risk of fracture during the first five years of administration . Animal studies, however, demonstrate an accumulation of microdamage and a lack of effective remodeling within bone after bisphosphonate use, which has been shown to compromise its biomechanical properties [9, 10]. In addition, a histomorphometric analysis of cancellous bone biopsy samples in nine patients sustaining spontaneous non-spinal fractures whilst on bisphosphonate therapy revealed markedly suppressed bone turnover . It has also been proposed that long-term bisphosphonate use may lead to secondary mineralization producing more brittle bones .
We describe a case of atypical bilateral proximal tibial and unilateral distal femoral insufficiency fractures in an adult woman who had been receiving tri-monthly intravenous pamidronate treatment for approximately six years.
A 76-year-old British Caucasian woman presented with a seven-month history of bilateral knee pain, caused initially by moving heavy furniture. Her symptoms were exacerbated on her left side after striking her knee against a parked car door five weeks prior to presentation. She could recall initial mild swelling which settled but no bruising. Her pain was worse when weight bearing, particularly on her left leg. An examination of her lower limbs was unremarkable except for tenderness over the medial proximal tibias bilaterally. She was initially diagnosed with cellulitis around her knee by the emergency department, though the C reactive protein was only mildly elevated at 23, and was prescribed 5 days oral flucloxacillin. Subsequent investigations for deep vein thrombosis by her primary care physician were negative and her symptoms persisted.
Her relevant medical history included seropositive erosive rheumatoid arthritis for over 30 years, osteomalacia and osteoporosis. Her relevant drug history included calcium 1200 mg/day, vitamin D3 800 units/day, prednisolone 5 mg/day, rabeprazole 20 mg/day, folic acid 10 mg once a week, intravenous methotrexate 15 mg once a week, and 30 mg intravenous pamidronate every three months. She had been taking prednisolone and methotrexate for seven years continuously. Blood tests revealed that her vitamin D, calcium, phosphate, parathyroid hormone and alkaline phosphatase levels were within normal limits.
Our patient had been treated with oral alendronate for three years but due to poor tolerance and compliance, her therapy was changed to intravenous pamidronate for the following six years. Measurement by dual-energy X-ray absorptiometry (DXA) was performed at her hip and lumbar vertebrae three years before bisphosphonate treatment was commenced and again three years after. Her T scores at her hip improved from -1.55 to -1.3 and at her lumber vertebrae from -2.86 to -2.5.
Our patient was referred to the orthopedic department where she stated her bilateral knee pains had now significantly improved. On examination, she was found to have a normal gait, mildly swollen knees bilaterally with tenderness over her left proximal medial tibia and a good equal range of knee, hip and ankle movement.
Her treatment consisted of bilateral knee supports, rest and protected weight bearing with crutches as tolerated until her symptoms fully resolved within two months.
A follow up DXA scan four months previously showed no significant change in her bone mineral density from the last result. No other changes were made to her drug therapy during or after this period.
Long-term bisphosphonate therapy has recently been associated with atypical proximal metaphyseal and diaphyseal femoral insufficiency fractures in a number of case series and reports [1–4, 6, 7, 12–14]. Large randomized trials, however, have not shown a significant increased risk or a causal relationship . This case highlights what we believe are atypical bilateral tibial and unilateral femoral insufficiency fractures occurring in a patient on long-term bisphosphonate therapy. Previous reports of atypical tibial insufficiency fractures are few in number [15, 16] and describe fractures of the tibial diaphysis as opposed to the proximal metaphyseal fractures seen in this case. Similarities of note between the cases are that one patient had rheumatoid arthritis , whilst the other patient was taking calcium and vitamin D supplements . All the patients were fully active prior to injury and the fractures were associated with minimal trauma.
The long-term oral corticosteroids and proton pump inhibitors which our patient was taking have been recognized as possible causes for increased fracture risk [4, 14, 17]. An increased risk of both vertebral and nonvertebral fractures has been reported with dosages of prednisolone or equivalent as low as 2.5 mg to 7.5 mg daily, and this risk may relate more strongly to daily rather than to cumulative doses of glucocorticoids . In a large meta-analysis, prior and current use of oral glucocorticoids increased the risk of any type of fracture, with no significant difference in relative risk between men and women .
There is also a link between methotrexate and insufficiency fractures, though in the context of rheumatoid arthritis this has not been as well established . Studies have shown increased urinary and fecal excretion of calcium in methotrexate use, indicating enhanced osteoclastic bone resorption, and toxic effects on osteoblasts resulting in osteopathy. There have also been case reports of tibia fractures in patients on low dose to intermediate dose methotrexate therapy .
Cases in the literature of atypical fractures in patients on bisphosphonate therapy include those who were not taking any of the above mentioned agents and so a direct causal relationship has yet to be found [2, 13].
Insufficiency fractures differ from stress fractures, in that the bone is abnormal in terms of mineralization, elasticity and ability to repair from injury, and so normal physiological activity can result in fracture . The majority of documented cases have occurred in patients using alendronate, which is the most commonly used bisphosphonate. However, atypical insufficiency fractures have also been reported amongst users of ibandronate, risedronate, zoledronate and pamidronate [2, 6, 7, 12, 13, 16, 23]. In a child with osteogenesis imperfecta, prolonged high dose administration of intravenous pamidronate has also been associated with the development of osteopetrosis .
Histomorphometric analysis of bone biopsy samples in patients taking alendronate has previously revealed severe suppression of bone turnover . Certainly the absence of this investigation in our described case is a limitation when attempting to establish an association between long-term bisphosphonate therapy and atypical insufficiency fractures. A bone biopsy could also have helped differentiate osteomalacia from osteoporosis as the underlying pathology.
It has been recommended that new onset thigh or hip pain in patients on long-term bisphosphonate therapy should be investigated with appropriate plain radiographs . We would extend this recommendation to bone or joint pain in any weight-bearing area, with or without a history of low-energy trauma. This is important as prodromal pain has been frequently reported in other series  and was also present in our case. It should be noted, however, that it can take between two and six weeks from the onset of symptoms to detect any radiographic changes.
Looser's zones are associated most frequently with osteomalacia , which could be a cause for these fractures. They have sclerotic irregular margins and are often symmetrical with wide transverse lucencies traversing the bone, usually at right angles to the involved cortex. These changes are present in the plain radiographs but are fairly subtle (Figure 1). Although our patient takes supplementation for the treatment of osteomalacia, her blood test results suggest this has been well controlled for a number of years. The typically described radiographic findings in previous case series of atypical insufficiency fractures of the proximal metaphysis and diaphysis of the femur, those of cortical thickening and a transverse fracture pattern, were also seen in our case though there was no cortical spiking or beaking [13, 15].
The well-known benefits of bisphosphonate treatment outweigh the relatively low risk of this rare group of atypical fractures. It also appears that, despite continuing bisphosphonate therapy, the majority of patients who sustain a fracture go on to make a full recovery within the expected timeframe. Further research is needed to provide guidance as to whether bisphosphonate therapy should be withheld whilst a patient is recovering from a fracture. More research is also needed to help identify any risk factors common to this subgroup of at-risk patients .
The above case highlights that atypical insufficiency fractures can also occur in other weight-bearing areas of the skeleton, such as the distal femur and proximal tibia. A high index of suspicion is recommended for early diagnosis and prompt treatment amongst all clinicians involved in the treatment of patients taking long-term bisphosphonates. This is particularly important as such patients are commonly taking other medications which have also been implicated in increasing the risk of fracture.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Capeci CM, Tejwani NC: Bilateral low energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009, 91: 2556-2561. 10.2106/JBJS.H.01774.View ArticlePubMedGoogle Scholar
- Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS: Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007, 89: 349-353. 10.1302/0301-620X.89B3.18146.View ArticlePubMedGoogle Scholar
- Neviaser AS, Lane JM, Lenart BA, Edobor-Osula E, Lorich DG: Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008, 22: 346-350. 10.1097/BOT.0b013e318172841c.View ArticlePubMedGoogle Scholar
- Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover; a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005, 90: 1294-1301.View ArticlePubMedGoogle Scholar
- Cheung RK, Leung KK, Lee KC, Chow TC: Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007, 13: 485-489.PubMedGoogle Scholar
- Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM: Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Oseoporosis Int. 2009, 20: 1353-1362. 10.1007/s00198-008-0805-x.View ArticleGoogle Scholar
- Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R: Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009, 32: 775-785. 10.2165/00002018-200932090-00002.View ArticlePubMedGoogle Scholar
- Tonino RP, Meunier PJ, Emkey R, Rodriquez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD: Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000, 85 (9): 3109-3115. 10.1210/jc.85.9.3109.PubMedGoogle Scholar
- Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001, 8 (5): 524-531.View ArticleGoogle Scholar
- Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res. 2000, 15: 613-620.View ArticlePubMedGoogle Scholar
- Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003, 349: 457-463. 10.1056/NEJMoa023110.View ArticlePubMedGoogle Scholar
- Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC: Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Eng J Med. 2010, 362 (19): 1761-1771. 10.1056/NEJMoa1001086.View ArticleGoogle Scholar
- Kewk EB, Goh SK, Koh JS, Png MA, Howe TS: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008, 39: 224-231. 10.1016/j.injury.2007.08.036.View ArticleGoogle Scholar
- Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008, 93: 2948-2952. 10.1210/jc.2007-2803.View ArticlePubMedGoogle Scholar
- Breglia MD, Carter J: Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheum. 2010, 16 (2): 76-78. 10.1097/RHU.0b013e3181cf3e3d.View ArticleGoogle Scholar
- Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS: Unusual mid shaft fractures during long term bisphosphonate therapy. Clin Endocrinol. 2010, 72 (2): 161-168. 10.1111/j.1365-2265.2009.03581.x.View ArticleGoogle Scholar
- Giusti A, Hamdy NAT, Papapoulos SE: Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone. 2010, 47: 169-180. 10.1016/j.bone.2010.05.019.View ArticlePubMedGoogle Scholar
- Van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005, 98: 191-198. 10.1093/qjmed/hci029.View ArticlePubMedGoogle Scholar
- Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004, 19: 893-899. 10.1359/JBMR.040134.View ArticlePubMedGoogle Scholar
- Degueker J, Maenaut K, Verwilghen J: Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol. 1995, 12: S21-S26.Google Scholar
- Meier L, van Tuyll van Sersooskerken AM, Liberton E, Kleijn L, Westgeest T, Polak M, Nijs R: Fractures of the proximal tibia associated with longterm use of methotrexate: 3 case reports and a review of the literature. J Rheumatol. 2010, 37 (11): 2434-2438. 10.3899/jrheum.100385.View ArticlePubMedGoogle Scholar
- Stephen AB, Wallace WA: The management of osteoporosis. J Bone Joint Surg Br. 2001, 83: 316-323. 10.1302/0301-620X.83B3.12196.View ArticlePubMedGoogle Scholar
- Patel VC, Lazzarini AM: Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use. Orthopaedics. 2010, 33 (10): 775-Google Scholar
- Yochum TR, Rowe LJ: Yochum and Rowe's Essentials of Skeletal Radiology. 2004, Philadelphia: Lippincott Williams and Wilkins, 1511-1514. 3Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.